ArticleScientific reports2025
Targeting SOX9: designing a novel vaccine against triple-negative breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype that lacks targeted therapies. This study aimed to design a novel multi-epitope peptide vaccine targeting SOX9, a transcription factor associated with TNBC progression. Using an immunoinformatic approach, B-cell, helper T lymphocyte (HTL), and cytotoxic T lymphocyte (CTL) epitopes with high antigenicity, non-toxicity, and non-allergenicity were identified. These epitopes were linked with appropriate spacers and fused to the 50 S ribosomal protein L7/L12 adjuvant to construct the vaccine. Physicochemical analysis predicted the construct to be stable, soluble, and suitable for expression. Structural modeling and refinement confirmed its quality, while molecular docking and dynamics simulations demonstrated favorable interactions with TLR2 and TLR4 receptors. Immune simulations predicted the strong cellular and humoral immune responses. These findings suggest that the designed vaccine holds substantial promise as a candidate for TNBC immunotherapy and merits further experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.